Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

7 Day Ceasefire Iran Offer, Trump-Xi AI Rivalry, More 10 min · 25 Sep 2026 · Bloomberg News Now

#685 - Joey Diaz 1h 59m · 25 Sep 2026 · This Past Weekend w/ Theo Von

NPR News: 09-25-2026 1AM EDT 5 min · 25 Sep 2026 · NPR News Now

1AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Same Yesterday, Today, and Forever 6 min · 25 Sep 2026 · Things Unseen with Sinclair B. Ferguson

The killer driver and member of Cock-Wall gang who poured bleach on elderly woman 22 min · 25 Sep 2026 · Crime World

Report any issue

Source

Recorded06 Mar 2026

Publisheraudiomedica.com ↗

Handlerec:19315676

Show notes

Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in